305 College Road East
Princeton, NJ 08540
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac (ADXS-HPV), an Lm-LLO immunotherapy product candidate, which completed its Phase II study used for the treatment of human papilloma virus (HPV) associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen (PSA) antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate the safety and efficacy of MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV; and Incyte Corporation for the development and analysis of a combination therapy for the treatment of cervical cancer. The company also has a licensing agreement with Global BioPharma, Inc.; development and commercialization agreement with Especificos Stendhal SA de CV.; and collaboration agreement with Amgen Inc. for the development and commercialization of Advaxis' ADXS-NEO, a preclinical investigational cancer immunotherapy treatment that activates patient's immune system to respond against mutations and neoepitopes. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.